Search results
Opko Health (OPK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoIn addition, we seek to bolster growth through the expansion of insurance coverage in our higher value specialty segments of oncology and urology, with...
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Lodi News-Sentinel· 1 day agoAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs ...
Outbreak of Highly Pathogenic Avian Influenza A(H5N1) Virus in Seals, St. Lawrence Estuary, Quebec,...
Centers for Disease Control and Prevention· 2 days agoAvian Influenza A(H5N1) Virus in Seals, Canada
OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ...
GuruFocus.com via Yahoo Finance· 3 days agoCost of Expenses: Decreased to $161.3 million in Q1 2024 from $172.4 million in Q1 2023. Pharmaceuticals Operating Loss: $27.7 million in Q1 2024 compared to... (NASDAQ:OPK ...
Tackling a Pathogen That Leaves a Lasting Impression
The Scientist· 5 days agoIn a recently published Cell Reports Medicine paper, researchers determined that previous exposures to the pathogen affect vaccine efficacy, where they...
Learn About How Xolair can Protect Against Food Allergies
1011 News· 3 days agoThe following content is created on behalf of Allergy, Asthma, and Immunology and does not reflect...
OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlight
Guru Focus· 4 days agoAsset Sale: Agreement to sell Bio-Reference health assets to LabCorp for $237.5 million.Revenue: Q1 2024 revenue for Diagnostics segment reported at $126.9 mil
What Is Multicentric Castleman Disease?
Healthline· 13 hours agoThis rare disease affecting the lymph nodes can increase your risk of developing lymphoma and life threatening infections. Multicentric Castleman disease is an immune system disease that affects ...
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
The Pilot News· 1 day agoCash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven's public offering completed
C3 Glomerulopathy Diagnosis
Medscape· 2 days agoC3 glomerulopathy (C3G) is a group of kidney diseases caused by dysregulation of the alternative complement pathway, resulting in abnormal deposition of...
